Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma

Abstract Diffuse large B cell lymphoma (DLBCL) is successfully treated with combination immuno-chemotherapy, but relapse with resistant disease occurs in ~ 40% of patients. However, little is known regarding relapsed/refractory DLBCL (rrDLBCL) genetics and alternative therapies. Based on findings fr...

Full description

Bibliographic Details
Main Authors: Alexandre Benoit, Elisabeth Bou-Petit, Hsiang Chou, Melissa Lu, Cynthia Guilbert, Vincent Mingyi Luo, Sarit Assouline, Ryan D. Morin, Svetlana Dmitrienko, Roger Estrada-Tejedor, Nathalie A. Johnson, Koren K. Mann
Format: Article
Language:English
Published: Nature Portfolio 2022-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-04736-0

Internet

https://doi.org/10.1038/s41598-021-04736-0

Similar Items